Current widely-accepted biomarkers for AD include cerebrospinal fluid levels of tau and amyloid-beta and amyloid positron emission tomography imaging, but these involve expensive and invasive procedures and are not routinely measured or accessible for patients (El Kadmiri et al., 2018). Here, MAPT is linked to Alzheimer disease.